Sleep Apnea + Weight Loss: How GLP-1s Are Replacing CPAP for Some Men

Zepbound is the first FDA-approved medication for obstructive sleep apnea. In real-world data, patients who started tirzepatide initiated CPAP therapy 83% less often. Here's what the clinical evidence actually supports.

Published May 1, 2026 · Last verified May 1, 2026

If you're a man with sleep apnea, you know the deal: you got diagnosed, you got a CPAP machine, and now there's a mask on your nightstand that you use inconsistently at best. CPAP works — when people actually use it. The compliance problem is enormous, and for decades, there hasn't been a real alternative. You either strap a machine to your face every night or you live with untreated sleep apnea and the cardiovascular risks that come with it.

That's changed. In December 2024, the FDA approved Zepbound (tirzepatide) as the first-ever medication specifically for obstructive sleep apnea in adults with obesity. The data behind the approval, and the real-world evidence emerging since, suggest this isn't a marginal benefit — it's a fundamental shift in how sleep apnea can be treated.

The SURMOUNT-OSA Trial: What It Found

The FDA approval was based on the SURMOUNT-OSA phase 3 clinical trial, a global, multi-center study that randomized 469 adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Participants received either tirzepatide (10mg or 15mg) or placebo for 52 weeks. The study included both CPAP users and non-users.

The primary endpoint was the apnea-hypopnea index (AHI) — the number of times per hour that breathing stops or becomes dangerously shallow during sleep. Higher AHI means more severe sleep apnea.

Participants on tirzepatide showed significant reductions in AHI, significant weight loss, and meaningful improvements in sleep quality scores. The results were robust in both the CPAP-using and non-CPAP groups, suggesting the medication works regardless of whether you're also using a breathing device.

Real-World Data: What Happened After Approval

A March 2026 analysis by Komodo Health examined real-world prescription data in the six months following the FDA approval (January–June 2025). The findings were striking:

The most notable finding: patients who received tirzepatide initiated CPAP therapy about 83% less often than those who didn't receive the medication. The drug is being used as an initial treatment step rather than a last resort after years of CPAP struggles — nearly a third of newly diagnosed OSA patients started it within 30 days of diagnosis.

Why This Matters More for Men

Obstructive sleep apnea disproportionately affects men. Men are approximately 2–3 times more likely to have OSA than women, and male anatomy — including higher rates of visceral fat deposition in the neck and abdomen — contributes to airway obstruction during sleep.

CPAP compliance is also particularly poor among men. The mask, the noise, the social stigma, the inconvenience for partners — these aren't trivial barriers. Studies consistently show that a significant percentage of CPAP users (estimates range from 30% to 50%) discontinue use within the first year.

The connection between OSA and other men's health issues compounds the problem. Untreated sleep apnea is associated with low testosterone, erectile dysfunction, cardiovascular disease, and cognitive impairment — essentially every issue that men over 40 are trying to address. Treating the sleep apnea improves all of these downstream conditions.

The Mechanism: More Than Just Weight Loss?

The primary mechanism is straightforward: weight loss reduces fat deposits around the upper airway and neck, which reduces physical obstruction during sleep. Semaglutide and tirzepatide both reduce visceral and subcutaneous fat in these regions.

But researchers are asking whether there's more to the story. A 2025 expert opinion published in a pharmacology journal noted that the question of whether GLP-1 benefits are purely weight-mediated or also involve direct respiratory effects remains open. Some evidence suggests GLP-1 receptor activation may affect respiratory drive and inflammatory pathways in the airway independently of weight loss.

A January 2026 study analyzing data from over 288,000 obese patients with OSA found that those who received GLP-1 medications alongside CPAP therapy had significantly lower rates of pulmonary hypertension and all-cause mortality compared to CPAP alone. This suggests potential additive benefits when the two approaches are combined rather than treated as either/or.

Which GLP-1 for Sleep Apnea?

Zepbound (tirzepatide) is currently the only GLP-1 medication with an FDA indication for OSA. It's also the medication studied in the SURMOUNT-OSA trial that formed the basis of approval. If you have insurance coverage or can access it through the new pricing programs, this is the evidence-based choice specifically for sleep apnea.

Semaglutide (Wegovy/Ozempic) does not have an FDA indication for sleep apnea, but the weight loss mechanism is similar. Clinical data shows semaglutide reduces neck fat and improves sleep-related metrics, though it hasn't been studied in a dedicated OSA trial at the same scale. Semaglutide is also FDA-approved for reducing cardiovascular events, which may be relevant given the cardiovascular comorbidity profile of OSA patients.

Compounded alternatives: Neither compounded semaglutide nor compounded tirzepatide carries an FDA indication for sleep apnea. That said, the weight loss mechanism is what drives the OSA benefit, and compounded versions produce meaningful weight loss in clinical practice. The decision between brand-name and compounded is a separate calculation from the OSA question.

Getting Started: What to Ask Your Provider

If you have sleep apnea and obesity, a conversation about GLP-1 therapy as part of your treatment plan is reasonable and well-supported by evidence. Here's what to discuss:

Request a baseline sleep study (if you haven't had one) — you need a documented AHI score to track improvement objectively.

Ask about tirzepatide specifically — given the FDA indication and SURMOUNT-OSA data, it has the strongest evidence base for OSA.

Discuss CPAP + GLP-1 combination — the emerging data suggests combining approaches may offer better outcomes than either alone, especially in severe OSA.

Plan for a follow-up sleep study at 6–12 months to objectively measure whether your AHI has improved enough to consider reducing or eliminating CPAP use.

Compounded medications are not FDA-approved. SHED pricing is dose-dependent and increases at higher doses. Confirm current pricing during intake.

Compounded medications are not FDA-approved.

The Bottom Line

For the first time in the history of sleep medicine, there's an FDA-approved medication that addresses the root cause of obesity-related sleep apnea rather than just managing the symptom. The real-world data — an 83% reduction in CPAP initiation among GLP-1 users — suggests patients and doctors are already voting with their prescriptions.

If you're a man with sleep apnea and obesity, GLP-1 therapy is no longer just about weight loss. It's about breaking the cycle of poor sleep, hormonal disruption, and metabolic decline that accelerates aging. Whether you use it alongside CPAP or potentially as a replacement (with documented AHI improvement), this is a conversation you should be having with your provider now — not after another year of inconsistent CPAP use.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.